Search

everythinglearnresearchcommunity

for

Search:↓

Research 10 of 1000+

1. Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients Frontiers in Medicine · 2025 · 2 citations
2. Table 1_Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients.docx Figshare · 2025
3. Supplementary file 1_Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients.docx Figshare · 2025
4. Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials 2022 · 25 citations
5. Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2 Journal of the European Academy of Dermatology and Venereology · 2024
6. Ixekizumab shows efficacy and safety in patients who failed biweekly etanercept therapy: Analysis From UNCOVER-2, a phase 3 randomized clinical trial in psoriasis Journal of The American Academy of Dermatology · 2016
7. Evaluation of the Tolerability of Hedgehog Pathway Inhibitors in the Treatment of Advanced Basal Cell Carcinoma: A Narrative Review of Treatment Strategies American Journal of Clinical Dermatology · 2024 · 10 citations
8. 267 Single- and multiple-ascending dose studies of DS-2325a, a KLK5 inhibitor for the treatment of Netherton syndrome Journal of Investigative Dermatology · 2024
9. LB1056 Phase 1b: Translational evaluation of VYN201, a pan-BD BET inhibitor, for the treatment of non-segmental vitiligo Journal of Investigative Dermatology · 2024 · 1 citations
10. Efficacy and safety of topical finasteride spray solution in the treatment of Chinese men with androgenetic alopecia: A phase III, multicenter, randomized, double-blind, placebo-controlled study Chinese Medical Journal · 2025

Community

— no results